Literature DB >> 16998933

Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma.

Elizabeth E Brown1, Denise Whitby, Francesco Vitale, Vickie Marshall, Georgina Mbisa, Christine Gamache, Carmela Lauria, Anthony J Alberg, Diego Serraino, Paola Cordiali-Fei, Angelo Messina, James J Goedert.   

Abstract

BACKGROUND: Classic Kaposi sarcoma (CKS) is an inflammatory-mediated neoplasm that develops in the presence of KS-associated herpesvirus (KSHV) and immune perturbation. In the current study, the authors compared CKS cases with age-matched and sex-matched KSHV-seropositive controls without human immunodeficiency virus-1 infection and markers of viral control, blood counts, CD4-positive and CD8-positive lymphocytes, and serum beta-2-microglobulin and neopterin levels.
METHODS: Viral loads were detected using real-time amplification of the KSHV-K6 and EBV-pol genes, anti-K8.1 (lytic) titers were detected by enzyme-linked immunoadsorbent assay, and antilatent nuclear antigen (LANA) titers were detected using immunofluorescence. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using logistic regression adjusted for sex, age, and study site.
RESULTS: Peripheral blood mononuclear cells (PBMC) KSHV DNA detection (P < or = .0001) and high KSHV lytic (>1:1745; P < or = .0001) and latent (>1:102,400; P = .03) antibody titers were found to be positively associated with CKS risk. Antibody titers were higher in cases with lesions compared with cases without lesions (P < or =.05). The detection of Epstein-Barr virus (EBV) DNA in PBMCs was not found to be associated with CKS (P = .95). Independent of PBMC KSHV DNA, CKS risk was found to be positively associated with reduced hematocrit (<37.4%; P = .03), hemoglobin (<12g/dL; P = .04), and lymphocytes (<1000 cells/microL; P = .004), including CD4-positive (+) cells (<457 cells/microL; P = .07) and CD8+ cells (<213cells/microL; P = .04), and with increased monocytes (> or =638 cells/microL; P = .009). Nonsignificant elevations of beta-2-microglobulin and neopterin were observed among cases regardless of disease burden (P > or = .08). In a multivariate model, the CKS risk was found to be associated with PBMC KSHV DNA (OR of 2.7; 95% CI, 1.4-5.3), a high KSHV lytic antibody titer (OR of 3.7; 95% CI, 1.9-7.4), and low lymphocytes, particularly among those patients age <70 years (OR of 8.0; 95% CI, 2.7-23.7).
CONCLUSIONS: The findings of the current study appear to corroborate the specificity of KSHV and highlight the hematologic and immunologic correlates involved in the pathogenesis of CKS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998933     DOI: 10.1002/cncr.22236

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV.

Authors:  Zhiqiang Qin; Michael DeFee; Jennifer S Isaacs; Chris Parsons
Journal:  Virology       Date:  2010-05-06       Impact factor: 3.616

2.  Review.

Authors:  Shawn Hancock; Patrick R Pfau
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

3.  Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus.

Authors:  Roberto Flores; James J Goedert
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

Review 4.  Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Denise Whitby
Journal:  Cancer Lett       Date:  2011-03-04       Impact factor: 8.679

5.  A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.

Authors:  Peter V Aka; Troy J Kemp; Charles S Rabkin; Meredith S Shiels; Mark N Polizzotto; Carmela Lauria; Francesco Vitale; Ligia A Pinto; James J Goedert
Journal:  J Infect Dis       Date:  2014-08-22       Impact factor: 5.226

6.  Seroprevalence of human herpesvirus 8 and its impact on the hemoglobin level in patients of end stage of renal diseases.

Authors:  Qiwen Fang; Xiaoyi Wang; Zhenqiu Liu; Ming Zhu; Min Ding; Veenu Minhas; Charles Wood; Tiejun Zhang
Journal:  J Med Virol       Date:  2017-09-22       Impact factor: 2.327

7.  Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.

Authors:  Emanuele Amodio; James J Goedert; Patrizia Barozzi; Giovanni Riva; Alberto Firenze; Filippa Bonura; Enza Viviano; Nino Romano; Mario Luppi
Journal:  Cancer Sci       Date:  2011-07-28       Impact factor: 6.716

8.  The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection.

Authors:  Jie Lu; Subhash C Verma; Qiliang Cai; Erle S Robertson
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

9.  CD4+ and CD8+ T-cell skewness in classic Kaposi sarcoma.

Authors:  Antonio Galleu; Claudio Fozza; Maria Pina Simula; Salvatore Contini; Patrizia Virdis; Giovanna Corda; Simonetta Pardini; Francesca Cottoni; Sara Pruneddu; Antonio Angeloni; Simona Ceccarelli; Maurizio Longinotti
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

10.  Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30.

Authors:  Colleen Pelser; Jaap Middeldorp; Sam M Mbulaiteye; Carmela Lauria; Angelo Messina; Enza Viviano; Nino Romano; Francesco Vitale; James J Goedert
Journal:  Infect Agent Cancer       Date:  2010-10-12       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.